Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 6;23(9):50.
doi: 10.1007/s11883-021-00952-1.

Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention

Affiliations
Review

Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention

Vardhmaan Jain et al. Curr Atheroscler Rep. .

Abstract

Purpose of review: This review highlights late-breaking science presented at the Virtual American College of Cardiology Scientific Sessions 2021 that demonstrated advancements in preventative cardiology and introduced novel therapeutic modalities for the management of chronic kidney disease, heart failure, and COVID-19.

Recent findings: The studies reviewed include clinical trials that assessed the use of dapagliflozin in patients with respiratory failure due to COVID-19 (DARE-19 trial); evinacumab for patients with severe hypertriglyceridemia and pancreatitis; effect of genotype-guided oral P2y12 inhibitors vs conventional clopidogrel on long-term ischemic outcomes after percutaneous coronary intervention (TAILOR-PCI trial); anticoagulation in patients hospitalized with COVID-19 (ACTION trial); atorvastatin vs placebo in patients with COVID-19 admitted to the ICU (INSPIRATION-S trial); rehabilitation therapy in older acute heart failure patients (REHAB-HF trial); and aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE trial). In addition, we review the results of the American College of Cardiology Global Heart Attack Initiative (GHATI). Finally, we discuss the secondary analysis of the STRENGTH trial assessing the association of achieved levels of omega-3 fatty acid levels and major cardiovascular outcomes. The studies presented at the virtual American College of Cardiology Scientific Session 2021 represent remarkable contributions in the field of cardiovascular disease and prevention.

Keywords: Aspirin; Dapagliflozin; Evinacumab; Omega-3 fatty acid; Rehabilitation; Severe hypertriglyceridemia.

PubMed Disclaimer

Conflict of interest statement

Salim Virani: Research support: Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org).

The other authors declare that they have no conflict of interest.

References

    1. Nissen SE, Lincoff AM, Wolski K, Ballantyne CM, Kastelein JJP, Ridker PM, Ray KK, McGuire DK, Mozaffarian D, Koenig W, Davidson MH, Garcia M, Katona BG, Himmelmann A, Loss LE, Poole M, Menon V, Nicholls SJ Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH trial. JAMA Cardiol. (2021) 10.1001/jamacardio.2021.1157 - PMC - PubMed
    1. Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;2021. 10.1056/NEJMoa2102137In a randomized trial of over 15,000 participants with established coronary artery disease randomized to receive either aspirin 81mg or aspirin 325mg, there was no difference in the rate of adverse cardiac events or major bleeding. However, there was significant dose switching in the group assigned to receive aspirin 325 mg.
    1. Kitzman DW, Whellan DJ, Duncan P, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021;2021. 10.1056/NEJMoa2026141In 349 older patients who were hospitalized for acute decompensated heart failure randomized to either routine care or an early, transitional, tailored, progressive rehabilitation intervention that included multiple physical-function domains, there was a greater improvement in physical function in the group that received rehabilitation than usual care. While there was no difference in all-cause mortality or rate of readmission, the improvement in functional status was clinically meaningful.
    1. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324:761–771. doi: 10.1001/jama.2020.12443. - DOI - PMC - PubMed
    1. Hussain A, Al Rifai M, Mahtta D, Liu J, Jain V, Virani SS. Highlights from studies presented at the American Heart Association Scientific Session 2020: navigating new roads in prevention. Curr Atheroscler Rep. 2020;23:1–9. - PMC - PubMed